3D conformal radiotherapy and cisplatin for recurrent malignant glioma

Canadian Journal of Neurological Sciences

Volumn 35, Issue 1, 2008, Pages 57-64

  VanderSpek, Lauren ^a,b   Fisher, Barbara ^a   Bauman, Glenn ^a   Macdonald, David ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; LEFLUNOMIDE; LOMUSTINE; MARIMASTAT; PACLITAXEL; PROCARBAZINE; STEROID; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGIC SKIN REACTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOW DRUG DOSE; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION NECROSIS; RADIATION RESPONSE; RECURRENT CANCER; THROMBOCYTOPENIA; TUMOR VOLUME; WEAKNESS;

EID: 42049099238     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100007563     Document Type: Article

References (67)

1. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511-9.
2. Nieder C, Grosu AL, Mehta MP, Andratschke N, Molls M. Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother. 2004;4:691-703.
3. Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold SC, Jr., et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55-7.
4. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907-11.
5. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43:79-88.
6. Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P. Is reoperation for recurrence of glioblastoma justified? Oncol Rep. 2000;7:899-904.
7. Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, et al. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys. 1996;36:433-41.
8. Brandes A, Vastola F, Monfardini S. Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Am J Clin Oncol. 1999;22:387-90.
9. Stupp R, Hegi M, van den Bent M, Mason W, Weller M, Mirimanoff R, et al. Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-80.
10. Butowski N, Sneed P, Chang S. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24: 1273-80.
11. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002;25:606-11.
12. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007;81(3):287-94.
13. Gutin P, Leibel S, Wara W, Choucair A, Levin V, Philips T, et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg. 1987;67:864-73.
14. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 1998;18:1303-11.
15. Glass J, Silverman C, Axelrod R, Corn B, Andrews D. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol. 1997;20:226-9.
16. Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo M. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;43:789-93.
17. Peiffert D. Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal. Cancer Radiother. 2003;7Suppl 1:100-7.
18. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527-39.
19. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-61.
20. Peters WA, III, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-13.
21. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-53.
22. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-80.
23. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Jr., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17: 1339-48.
24. Sharma VM, Wilson WR. Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy. Eur Arch Otorhinolaryngol. 1999;256:462-5.
25. Sauer R, Dunst J, Altendorf-Hofmann A, Fischer H, Bornhof C, Schrott KM. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys. 1990;19:687-91.
26. Stewart D, Leavens M, Maor M, Feun L, Luna M, Bonura J, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982;42:2474-9.
27. Chamberlain M, Barba D, Komanik P, Benson A, Saunders W, Shea M. Toxicity and safety study of concurrent cisplatin and 1125 brachytherapy. Arch Neurol. 1995;52:162-7.
28. Shepherd S, Laing R, Cosgrove V, Warrington A, Hines F, Ashley S, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393-8.
29. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000; 47:291-8.
30. Macdonald D, Cascino T, Schold SJ, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-80.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
32. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. ICRU Report 50. 50. Bethesda, MD; 1993.
33. Lichter A, Sandler H, Robertson J, Lawrence T, Ten Haken R, McShan D, et al. Clinical experience with three-dimensional treatment planning. Semin Radiat Oncol. 1992;2:257-66.
34. Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, Roujeau T, et al. Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma. Bull Cancer. 2005;92:333-42.
35. Larson D, Prados M, Lamborn K, Smith V, Sneed P, Chang S, et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002;54:1397-404.
36. Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M. Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys. 1998;40:661-6.
37. Schafer U, Micke O, Schuller P, Schuck A, Willich N. The effect of sequential radiochemotherapy in preirradiated malignant gliomas in a phase II study. J Neurooncol. 2004;67:233-9.
38. Schonekaes K, Mucke R, Panke J, Rama B, Wagner W. Combined radiotherapy and temozolomide in patients with recurrent high grade glioma. Tumori. 2002;88:28-31.
39. Laing W, Warrington A. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). Radiother Oncol. 1993;27:22-9.
40. Hudes R, Corn B, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:293-9.
41. Vordermark D, Kolbl O, Ruprecht K, Vince G, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55.
42. Dhermain F, de Crevoisier R, Parker F, Cioloca C, Kaliski A, Beaudre A, et al. Role of radiotherapy in recurrent gliomas. Bull Cancer. 2004;91:883-9.
43. Flickinger J, Kondziolka D, Pollock B, Maitz A, Lunsford L. Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling. Int J Radiat Oncol Biol Phys. 1997;38:485-90.
44. Cho K, Hall W, Gerbi B, Higgins P, McGuire W, Clark H. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;45: 1133-41.
45. Schultheiss T, Kun L, Ang K, Stephens L. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995;31:1093-112.
46. Shapiro W, Green S, Burger P, Mahaley MJ, Selker R, VanGilder S, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71:1-9.
47. Enami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
48. Sheline G, Wara W, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215-28.
49. Flickinger J, Deutsch M, Lunsford L. Repeat megavoltage irradiation of pituitary and suprasellar tumors. Int J Radiat Oncol Biol Phys. 1989;17:171-5.
50. Flickinger J, Lunsford L, Kondziolka D. Dose prescription and dose-volume effects in radiosurgery. Neurosurg Clin N Am. 1992;3:51-9.
51. Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Phase II, two-arm RTOG trial (94-11) of bischloroethylnitrosurea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys. 2000;48:1351-8.
52. Wood J, Green S, Shapiro W. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988;6:338-43.
53. Curran W, Scott C, Weinstein A, Martin L, Nelson J, Phillips T, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol. 1993;11:857-62.
54. Stupp R, van den Bent M, Hegi M. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5:198-206.
55. Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
56. Stupp R, Pavlidis N, Jelic S. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up in malignant glioma. Ann Oncol. 2005;16:i64-i65.
57. Douple E, Richmond R. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys. 1982;8:501-3.
58. Fu K. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer. 1985;55:2123-30.
59. Phillips T, Fu K. The interaction of drug and radiation effects on normal tissues. Int J Radiat Oncol Biol Phys. 1978;4:59-64.
60. Douple E, Eaton W, Tulloh M. Skin radiosensitization studies using combined cis-dichlorodiaminneplatinum (II) and radiation. Int J Radiat Oncol Biol Phys. 1979;5:1383-5.
61. Wilkins D, Ng C, Raaphorst G. Cisplatin and low dose rate irradiation in cisplatin resistant and sensitive human glioma cells. Int J Radiat Oncol Biol Phys. 1996;36:105-11.
62. Sheleg S, Korotkevich E, Zhavrid E, Muravskaya G, Smeyanovich A, Shanko Y, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol. 2002;60:53-9.
63. Thompson S, Davis L, Kornfeld M, Hilgers R, Standefer J. Cisplatin neuropathy, clinical, electrophysiology, morphologic, and toxicologic studies. Cancer. 1984;54:1269-75.
64. Stewart D, Leavens M, Maor M, Feun L, Luna M, Bonura J, et al. Human central nervous system distribution of cis-Diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982;42:2474-9.
65. Rich J, Reardon D, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133-42.
66. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-15.
67. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: the polymer-brain tumor treatment group. Lancet. 1995;345:1008-12.